Our Vision: "Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
我們正在追蹤 WuXi Biologics/药明生物 的市場擴張
全新 業務版圖 活動 — 剛出現 9 個新訊號。
WuXi Biologics/药明生物 的國際擴張與競爭對手的比較
WuXi Biologics/药明生物你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 WuXi Biologics/药明生物你 | 0 | 0 | — | 0 | 0 |
Talent Acquisition Specialist
查看招聘Tuas, West Region, Singapore · 昨日
Manufacturing Manager/ Senior Manager, Lyophilization Drug Product Operations
查看招聘Singapore, Singapore · 昨日
Supply Chain Senior Manager (Import & Export Biomaterial)
查看招聘Singapore, Singapore · 前日
藥明生物宣布其位於上海的藥品設施15獲得GMP認證,這是其全球第18個運營藥品設施,配備先進無菌灌裝能力,支持臨床階段生物製劑項目。
藥明生物位於上海奉賢的DP15廠房於4月獲得GMP放行,成為公司全球第18個生物製劑生產廠,配備先進灌裝產線。
藥明生物發布2025年可持續發展報告,強調對醫療公平、治理透明度、員工賦能、氣候行動及綠色CRDMO解決方案的承諾。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 WuXi Biologics/药明生物 業務、市場及增長訊號的快速解答。
